Despite improved surgical treatment and modern chemotherapy the prognosis in advanced ovarian cancer is poor, mainly due to observed tumour chemoresistance against protocols based on cisplatin and taxanes. The paper describes different forms of immunopotentiation of the anti-cancer host response based on immunotherapy with the use of monoclonal antibodies, cytokines, dendritic cell vaccines or activated T cells. Immunotherapy used separately or in combination with chemotherapy could, at least to some extent, enhance the efficacy of ovarian cancer treatment.